TGTX
TG Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 7, 7:33 AM
    • TG Therapeutics (NASDAQ:TGTX): Q3 EPS of -$0.50 misses by $0.19.
    • Revenue of $0.04M (flat Y/Y) beats by $0.01M.
    • Press Release
    | Mon, Nov. 7, 7:33 AM
  • Thu, Oct. 13, 12:47 PM
    | Thu, Oct. 13, 12:47 PM | 6 Comments
  • Thu, Oct. 13, 11:00 AM
    | Thu, Oct. 13, 11:00 AM
  • Thu, Oct. 13, 9:28 AM
    • Thinly traded micro cap TG Therapeutics (NASDAQ:TGTX) is down 15% premarket on increased volume in response to its announcement that it has filed a request with the FDA to amend the protocol in its Phase 3 study, GENUINE, assessing lead product candidate TG-1101 in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL).
    • The amended protocol, if approved, will drop progression-free survival (PFS) as an efficacy endpoint (Part II of the study) with overall response rate (ORR) serving as the sole primary endpoint (Part I). Enrollment in the revised study should be completed this quarter with top-line data expected in H1 2017.
    | Thu, Oct. 13, 9:28 AM | 3 Comments
  • Thu, Oct. 13, 9:20 AM
    | Thu, Oct. 13, 9:20 AM | 1 Comment
  • Fri, Oct. 7, 11:48 AM
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) initiated with Buy rating and $26 (38% upside) price target by H.C. Wainwright.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and $22 (54% upside) price target by H.C. Wainwright.
    • Mazor Robotics (NASDAQ:MZOR) initiated with Buy rating and $25 (10% upside) price target by B. Riley.
    • Lipocine (NASDAQ:LPCN) initiated with Buy rating and $25 (350% upside) price target by H.C. Wainwright.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating and $28 (218% upside) price target by Brean Capital.
    • Immunomedics (NASDAQ:IMMU) initiated with Buy rating and $5.50 (113% upside) price target by Jefferies.
    • AmerisourceBergen (NYSE:ABC) initiated with Neutral rating by UBS.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Buy rating and $22 (65% upside) price target by SunTrust Robinson Humphrey.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $6 (92% upside) price target by Cantor Fitzgerald.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) initiated with Buy rating and $17 (94% upside) price target by Cantor Fitzgerald.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (142% upside) price target by Brean Capital.
    • Zogenix (NASDAQ:ZGNX) initiated with Outperform rating and $17 (64% upside) price target by Leerink Swann.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $162 (23% upside) price target by Leerink Swann. Initiated with Buy rating and $189 (44% upside) price target by Goldman Sachs.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Outperform rating and $68 (57% upside) price target by Leerink Swann.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $221 (79% upside) price target by Brean Capital.
    • Axsome Therapeutics (NASDAQ:AXSM) initiated with Buy rating and $20 (136% upside) price target by Brean Capital.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (156% upside) price target by Brean Capital.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $16 (226% upside) price target by Brean Capital.
    • Sorrento Therapeutics (NASDAQ:SRNE) initiated with Buy rating and $15 (94% upside) price target by Roth Capital.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Outperform rating and a $75 - 81 (322% upside from midpoint) target price range by Wells Fargo.
    • Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Buy rating and $45 (49% upside) price target by Brean Capital.
    | Fri, Oct. 7, 11:48 AM | 8 Comments
  • Mon, Aug. 29, 11:00 AM
    | Mon, Aug. 29, 11:00 AM
  • Fri, Aug. 26, 8:57 AM
    • The FDA designates TG Therapeutics' (NASDAQ:TGTX) lead product candidate TG-1101 (ublituximab), a glycoengineered anti-CD20 monoclonal antibody, an Orphan Drug for the treatment of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD).
    • NMO, known as Devic's disease, is an autoimmune disorder characterized by the inflammation and demyelination of the optic nerve and spinal cord. It is often misdiagnosed as multiple sclerosis (MS). It affects only ~1,500 Americans.
    • NMOSD is a unifying term encompassing NMO and related syndromes involving the brainstem and hypothalamus. It accounts for 1 - 3% of MS-line illness.
    • There are no cures for the disorders. The current standard-of-care is steroid therapy to address the inflammation.
    • TG-1101 is also under development (Phase 2) for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple sclerosis.
    • Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
    | Fri, Aug. 26, 8:57 AM
  • Wed, Aug. 24, 12:48 PM
    | Wed, Aug. 24, 12:48 PM
  • Mon, Aug. 8, 7:32 AM
    • TG Therapeutics (NASDAQ:TGTX): Q2 EPS of -$0.33 misses by $0.04.
    • Revenue of $0.04M in-line (flat Y/Y).
    • Press Release
    | Mon, Aug. 8, 7:32 AM
  • Fri, May 27, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    | Fri, May 27, 4:56 PM | 17 Comments
  • Tue, May 10, 4:11 PM
    • TG Therapeutics (NASDAQ:TGTX): Q1 EPS of -$0.28 beats by $0.08.
    • Revenue of $0.04M (flat Y/Y) beats by $0.01M.
    | Tue, May 10, 4:11 PM
  • Mon, Mar. 7, 4:32 PM
    • TG Therapeutics (NASDAQ:TGTX): Q4 EPS of -$0.37 misses by $0.05.
    • Revenue of $0.04M in-line (flat Y/Y).
    | Mon, Mar. 7, 4:32 PM
  • Nov. 9, 2015, 7:35 AM
    • TG Therapeutics (NASDAQ:TGTX): Q3 EPS of -$0.28 beats by $0.06.
    • Revenue of $0.04M in-line (flat Y/Y).
    | Nov. 9, 2015, 7:35 AM
  • Sep. 17, 2015, 12:41 PM
    | Sep. 17, 2015, 12:41 PM | 8 Comments
  • Sep. 17, 2015, 9:15 AM
    | Sep. 17, 2015, 9:15 AM